Company overview
Tagomics is a biomarker discovery and diagnostics company offering a proprietary multiomics platform that integrates genomics, epigenomics, and fragmentomics to unlock disease-associated biomarkers from biological sources. The company's Interlace platform combines novel epigenomic profiling with advanced machine learning to provide comprehensive disease insights, with a focus on early cancer detection through blood-based liquid biopsy tests.
Multiomics Biomarker Discovery & Diagnostics is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include multiomics platform, biomarker discovery, liquid biopsy, epigenomics, cancer diagnostics, genomics.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Multiomics Biomarker Discovery & Diagnostics include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://tagomics.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- multiomics platform, biomarker discovery, liquid biopsy, epigenomics, cancer diagnostics, genomics, fragmentomics, early cancer detection
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is Tagomics' core technology platform?
- Tagomics has developed the Interlace multiomics platform, which seamlessly integrates three complementary technologies: genomics (detecting mutations and structural variants), epigenomics (analyzing chemical modifications on the genome), and fragmentomics (analyzing DNA fragmentation patterns in blood). The platform applies advanced data analysis and machine learning to provide 360-degree understanding of human health and disease.
- What are the primary applications for pharmaceutical and diagnostics companies?
- Tagomics' platform is designed for biomarker discovery, early cancer detection through liquid biopsy, drug development support, and therapy selection for patients. The company aims to make early cancer detection accessible through simple, accurate blood tests to improve patient survival and quality of life.
- What recent technological advances has Tagomics published?
- In September 2025, Tagomics published peer-reviewed research in Cell Reports Methods describing Active-Seq, a base conversion-free methodology for genome-wide epigenomic profiling. This technology forms the basis of the Activace platform, which provides targeted, genome-wide profiling of unmethylated DNA regions and has been applied to biomarker identification in colorectal cancer patients.
- Where is Tagomics located and what is its background?
- Tagomics is based in Cambridge, United Kingdom, and was launched in 2021 as a spin-out from the University of Birmingham, building on research led by Chief Scientific Officer Dr. Robert Neely. The company raised £6.7 million in funding to advance disease diagnosis and develop strategic partnerships.
Related editorial coverage
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
